CBLL
NASDAQCeriBell Inc.
Price$25.05-2.36 (-8.63%)
01:30 PM07:45 PM
News · 26 weeks64-82%
2026-04-192026-10-11
Mix3390d
- Insider22(67%)
- Other5(15%)
- SEC Filings3(9%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- INSIDERChief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $119,145 worth of shares (4,887 units at $24.38) as part of a pre-agreed trading plan (SEC Form 4)4 - Ceribell, Inc. (0001861107) (Issuer)
- PRCeribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG AnalysisSUNNYVALE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared new software for the Ceribell System that makes it easier and faster for clinicians to interpret longitudinal brain activity and make appropriate clinical decisions.1 Brain monitoring with electroencephalography (EEG) can generate hours of complex data that can be difficult to interpret in a timely manner. Ceribell's newly cleared software takes that raw information and t
- INSIDERPresident and CEO Chao Xingjuan sold $521,775 worth of shares (20,846 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 746,345 units (SEC Form 4)4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERChief Financial Officer Blumberg Scott sold $21,150 worth of shares (846 units at $25.00) as part of a pre-agreed trading plan and exercised 846 shares at a strike of $9.41 (SEC Form 4)4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERSenior VP, Finance and PAO Foehr David sold $224,451 worth of shares (9,255 units at $24.25) as part of a pre-agreed trading plan and exercised 7,500 shares at a strike of $4.70, decreasing direct ownership by 5% to 34,144 units (SEC Form 4)4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERChief Technology Officer Woo Raymond exercised 13,276 shares at a strike of $2.76 and sold $118,901 worth of shares (4,887 units at $24.33) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 203,118 units (SEC Form 4)4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERPresident and CEO Chao Xingjuan sold $973,079 worth of shares (39,540 units at $24.61) as part of a pre-agreed trading plan and exercised 25,000 shares at a strike of $4.70, decreasing direct ownership by 2% to 767,191 units (SEC Form 4)4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERChief Financial Officer Blumberg Scott exercised 652 shares at a strike of $9.41 and sold $16,300 worth of shares (652 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERChief Revenue Officer Manni Joseph S. sold $32,691 worth of shares (1,361 units at $24.02), decreasing direct ownership by 2% to 55,956 units (SEC Form 4) (tax liability)4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERSenior VP, Finance and PAO Foehr David sold $44,425 worth of shares (1,852 units at $23.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 35,899 units (SEC Form 4) to cover withholding tax4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERChief Technology Officer Woo Raymond sold $47,536 worth of shares (1,979 units at $24.02), decreasing direct ownership by 1% to 194,729 units (SEC Form 4) (for tax liability)4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERChief Financial Officer Blumberg Scott sold $36,534 worth of shares (1,521 units at $24.02), decreasing direct ownership by 1% to 146,600 units (SEC Form 4) (tax liability)4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERPresident and CEO Chao Xingjuan sold $145,753 worth of shares (6,068 units at $24.02), decreasing direct ownership by 0.77% to 781,731 units (SEC Form 4) to satisfy withholding tax4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERChief Financial Officer Blumberg Scott exercised 34,502 shares at a strike of $8.47 and sold $863,555 worth of shares (34,502 units at $25.03) as part of a pre-agreed trading plan (SEC Form 4)4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Financial Officer Blumberg Scott4/A - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERPresident and CEO Chao Xingjuan sold $841,292 worth of shares (33,614 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 787,799 units (SEC Form 4)4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERPresident and CEO Chao Xingjuan exercised 33,096 shares at a strike of $3.31, increasing direct ownership by 4% to 821,413 units (SEC Form 4)4 - Ceribell, Inc. (0001861107) (Issuer)
- INSIDERDirector Taylor Joseph Michael sold $306,423 worth of shares (13,095 units at $23.40), decreasing direct ownership by 21% to 48,478 units (SEC Form 4)4 - Ceribell, Inc. (0001861107) (Issuer)
- SECSEC Form 10-Q filed by CeriBell Inc.10-Q - Ceribell, Inc. (0001861107) (Filer)
- SECCeriBell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Ceribell, Inc. (0001861107) (Filer)
- PRCeribell Reports Second Quarter 2026 Financial ResultsSUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 & Recent Highlights Reported total revenue of $28.1 million in the second quarter of 2026, a 33% increase compared to the same period in 2025Ended the quarter with 712 total active accountsAchieved gross margin of 92%, which includes impact of refunds from previously paid tariffsReceived U.S. Food and Drug Administration 510(k) clearances for Epileptiform Abnormality
- PRCeribell Receives FDA Clearance for Advanced Epileptiform Abnormality Detection and Artifact Reduction for Its Cloud-Based Portal, Delivering Greater Precision for Critical-Care EEG ReviewSUNNYVALE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for two new AI algorithm enhancements integrated directly into its existing cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction.1 These new capabilities expand the clinical utility of the Ceribell Point-of-Care (POC) brain monitoring system, providing neurologists and bedside practitioners with an enhanced toolset for rapid, high-confidence e
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CeriBell Inc.SCHEDULE 13G/A - Ceribell, Inc. (0001861107) (Subject)
- INSIDERPresident and CEO Chao Xingjuan exercised 25,000 shares at a strike of $4.70 and sold $714,480 worth of shares (39,000 units at $18.32) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 788,317 units (SEC Form 4)4 - Ceribell, Inc. (0001861107) (Issuer)
- PRCeribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor SystemSUNNYVALE, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for up to $2,171 per eligible Medicare patient case utilizing the Ceribell Delirium Monitor System.1 This follows the December 2025 U.S. Food and Drug Administration (FDA) 510(k) clearance of Ceribell’s proprietary Delirium Monitor System,2 establishing it as the first and only FDA-cleared device used to aid in delirium sc
CBLL FAQ
6 questionsWhere does CBLL stock trade?
CeriBell Inc. (CBLL) is listed on NASDAQ.What sector and industry is CBLL in?
CeriBell Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did CeriBell Inc. go public?
CeriBell Inc. (CBLL) completed its IPO in 2024.What are analysts saying about CBLL?
CeriBell Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $1900.00 price target on 2025-10-21. Recent price targets range from $1900.00 to $3200.00.What companies are similar to CBLL?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare CBLL side-by-side with any of them on Quantisnow.How can I track CBLL on Quantisnow?
Quantisnow aggregates CeriBell Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CBLL to receive live email and push alerts on every new disclosure.